5619-09-0

Basic information

• Product Name: DL-TRYPTOPHAN METHYL ESTER HYDROCHLORIDE
• Synonyms: H-DL-TRP-OME HCL;DL-TRYPTOPHAN METHYL ESTER HCL;DL-TRYPTOPHAN METHYL ESTER HYDROCHLORIDE;DL-TRYPTOPHAN-OME HCL;METHYL 2-AMINO-3-(1H-INDOL-3-YL)PROPANOATE HYDROCHLORIDE;TIMTEC-BB SBB003122;methyl2-amino-3-(1H-indol-3-yl)propanoateHCl;DL-Methyl Tryptophanate Monohydrochloride
• CAS NO: 5619-09-0
• Molecular Formula: C₁₂H₁₄N₂O₂*ClH
• Molecular Weight: 254.71
• EINECS: 1533716-785-6
• Product Categories: Amino Acids 13C, 2H, 15N;Amino Acids & Derivatives
• Mol File: 5619-09-0.mol

Chemical Properties

• Melting Point: 221-222
• Boiling Point: 390.6 °C at 760 mmHg
• Flash Point: 190 °C
• Appearance: Off-white to white/Solid
• Density: 1.245g/cm3
• Vapor Pressure: 2.62E-06mmHg at 25°C
• Storage Temp.: 2-8°C
• Solubility: Methanol, Water
• CAS DataBase Reference: DL-TRYPTOPHAN METHYL ESTER HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: DL-TRYPTOPHAN METHYL ESTER HYDROCHLORIDE(5619-09-0)
• EPA Substance Registry System: DL-TRYPTOPHAN METHYL ESTER HYDROCHLORIDE(5619-09-0)

Safety Data

• Hazard Codes: Xi,Xn
• Hazardous Substances Data: 5619-09-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
DL-Tryptophan Methyl Ester Hydrochloride is used as an intermediate in the synthesis of L-Tryptophanamide Hydrochloride (Cat. #T89550), a compound with potential therapeutic applications. This amino acid amide can be further utilized in the development of new drugs and pharmaceutical formulations, targeting a wide range of medical conditions.
Used in Research and Development:
As an amino acid derivative, DL-Tryptophan Methyl Ester Hydrochloride is also used in research and development settings to explore its potential applications in the creation of novel bioactive molecules, drug delivery systems, and other innovative therapeutic approaches. Its versatility in forming esters and amides makes it a valuable tool for scientists working in the fields of medicinal chemistry and drug discovery.

InChI:InChI=1/C12H14N2O2.ClH/c1-16-12(15)10(13)6-8-7-14-11-5-3-2-4-9(8)11;/h2-5,7,10,14H,6,13H2,1H3;1H

Upstream product

• 118553-32-5 Methyl N-(diphenylmethylene)-D,L-tryptophanates 
• 67-56-1 methanol 
• 54-12-6 Trp 
• 120-72-9 indole 
• 1198605-52-5 methyl (S)-2-((tert-butoxycarbonyl)amino)-3-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indol-3-yl)propanoate 
• 141215-69-2 methyl (2S)-2-{[(tert-butoxy)carbonyl]amino}-3-(1H-indol-3-yl)propanoate 
• 73-22-3 L-Tryptophan 
• 6159-33-7 L-tryptophan hydrochloride 
• 5619-09-0 methyl tryptophanate hydrochloride 
• 153-94-6 D-tryptophan 
• 141595-98-4 D-tryptophan benzyl ester 
• 153-94-6 D-tryptophan 

Downstream Products

• 141215-69-2 N-(tert-butyloxycarbonyl)-2-(3-indolyl)glycin methyl ester 
• 145401-81-6 (R)-α-methylbenzylcarbamoyl-DL-tryptophan methyl ester 
• 77714-32-0 3-(1H-Indol-3-yl)-2-((Z)-3-oxo-propenylamino)-propionic acid methyl ester 
• 77714-32-0 3-(1H-Indol-3-yl)-2-((E)-3-oxo-propenylamino)-propionic acid methyl ester 
• 79397-25-4 2-[2-(4-Chloro-phenoxy)-acetylamino]-3-(1H-indol-3-yl)-propionic acid methyl ester 
• 79397-35-6 2-[(Z)-2-(4-Chloro-phenoxy)-3-(4-nitro-phenyl)-acryloylamino]-3-(1H-indol-3-yl)-propionic acid methyl ester 
• 144426-38-0 3-(1H-Indol-3-yl)-2-{2-[4-((E)-styryl)-phenoxy]-acetylamino}-propionic acid methyl ester 
• 144426-46-0 2-(2-{4-[(E)-2-(4-Chloro-phenyl)-vinyl]-phenoxy}-acetylamino)-3-(1H-indol-3-yl)-propionic acid methyl ester 
• 144426-47-1 3-(1H-Indol-3-yl)-2-{2-[4-((E)-styryl)-phenoxy]-propionylamino}-propionic acid methyl ester 
• 7303-49-3 DL-tryptophan methyl ester 
• 53399-48-7 trans-(3-(methoxycarbonyl)-1,2,3,4-tetrahydro-9H-pyrido<3,4-b>indol-1-yl)(2-nitrobenzene) 
• 53399-48-7 cis-(3-(methoxycarbonyl)-1,2,3,4-tetrahydro-9H-pyrido<3,4-b>indol-1-yl)(2-nitrobenzene) 
• 104331-05-7 rac-3-(1H-indol-3-yl)-2-(benzoylamino)propionic acid methyl ester 
• 2717-77-3 Z(NO₂)-Trp-OMe 

Relevant articles and documents

Lithocholic acid-tryptophan conjugate (UniPR126) based mixed micelle as a nano carrier for specific delivery of niclosamide to prostate cancer via EphA2 receptor

Targeted delivery of chemotherapeutic agents is considered a prominent strategy for the treatment of cancer due to its site-specific delivery, augmented penetration, bioavailability, and improved therapeutic efficiency. In the present study, we employed UniPR126 as a carrier in a mixed nanomicellar delivery system to target and deliver anticancer drug NIC specifically to cancer cells via EphA2 receptors as these receptors are overexpressed in cancer cells but not in normal cells. The specificity of the carrier was confirmed from the significant enhancement in the uptake of coumarin-6 loaded mixed nanomicelle by EphA2 highly expressed PC-3 cells compared to EphA2 low expressed H4 cells. Further, niclosamide-loaded lithocholic acid tryptophan conjugate-based mixed nanomicelle has shown significant synergistic cytotoxicity in PC-3 but not in H4 cells. In vivo anticancer efficacy data in PC-3 xenograft revealed a significant reduction in the tumor volume (66.87%) with niclosamide-loaded lithocholic acid tryptophan conjugate nanomicelle, where pure niclosamide showed just half of the activity. Molecular signaling data by western blotting also indicated that niclosamide-loaded lithocholic acid tryptophan conjugate nanomicelle interfered with the EphA2 receptor signaling and inhibition of the Wnt/beta-catenin pathway and resulted in the synergistic anticancer activity compared to niclosamide pure drug.

Translation of Mycobacterium Survival Strategy to Develop a Lipo-peptide based Fusion Inhibitor**

The entry of enveloped virus requires the fusion of viral and host cell membranes. An effective fusion inhibitor aiming at impeding such membrane fusion may emerge as a broad-spectrum antiviral agent against a wide range of viral infections. Mycobacterium survives inside the phagosome by inhibiting phagosome–lysosome fusion with the help of a coat protein coronin 1. Structural analysis of coronin 1 and other WD40-repeat protein suggest that the trp-asp (WD) sequence is placed at distorted β-meander motif (more exposed) in coronin 1. The unique structural feature of coronin 1 was explored to identify a simple lipo-peptide sequence (myr-WD), which effectively inhibits membrane fusion by modulating the interfacial order, water penetration, and surface potential. The mycobacterium inspired lipo-dipeptide was successfully tested to combat type 1 influenza virus (H1N1) and murine coronavirus infections as a potential broad-spectrum antiviral agent.

Convenient method for the synthesis of some novel chiral methyl 2-(2-oxo-2H-benzo[e][1,3]oxazin-3(4H)-yl)propanoate derivatives and biological evaluation of their antioxidant, cytotoxic, and molecular docking properties

Ten chiral methyl 2-(2-oxo-2H-benzo[e][1,3]oxazin-3(4H)-yl)propanoate derivatives 6a-6j have been synthesized from optically pure amino methyl phenol 5 and 4-nitrophenyl chloroformate. These derivatives 6a-6j are characterized by 1H NMR, 13C NMR, FT-IR, and HRMS spectral techniques. Optical purity of these derivatives was confirmed by chiral HPLC method. Ten synthesized ester derivatives 6a-6j were screened for their in vitro antioxidant activity. Among the compounds 6b-d and 6h-j have exhibited comparable antioxidant activity with ascorbic acid as a standard. Compounds 6a and 6e-g have shown moderate antioxidant activity. Further, the in vitro cytotoxicity of these compounds were studied through MTT cell proliferation assay in addition the effect on LDH leakage and NO release. Among the derivatives, 6j showed extremely best activity and the IC50 value (12.54 ± 0.71 μM) is very close to doxorubicin (7.2 ± 0.58 μM) as a standard. Compounds 6b, 6h, and 6i showed better inhibition next to compound 6j on the viability of HepG2 cells with an IC50 value (μM) of 56.02 ± 1.4, 41.76 ± 0.58, and 38.17 ± 0.34, respectively. Also, molecular docking studies have been carried out with STAT-3 (PDB ID: 1BG1) and BCL-2 (PDB ID: 4AQ3) proteins against the four active compounds 6b, 6h, 6i, and 6j. The binding energies of the tested compounds were in the range of ?7.76 to ?8.41 kcal/mol, which is very close to doxorubicin (?8.53 kcal/mol) as a standard. These molecular docking results are in good agreement with the in vitro studies.

A fast and direct iodide-catalyzed oxidative 2-selenylation of tryptophan

A metal-free 2-selenylation of tryptophan derivatives is reported, where the use of iodide as the catalyst and oxone as the oxidant is key to obtain high yields. Various functional groups within the di-seleny and the indole ring are tolerated, and no racemization is generally observed.

Ribose conversion with amino acids into pyrraline platform chemicals-expeditious synthesis of diverse pyrrole-fused alkaloid compounds

One-pot conversion of sustainable d-ribose with l-amino acid, methyl esters produced pyrrole-2-carbaldehydes 5 in reasonable yields (32-63%) under pressurized conditions of 2.5 atm at 80 °C. The value-added pyrraline compounds 5 as platform chemicals were utilized for quick installation of poly-heterocyclic cores for the development of pyrrole-motif natural and artificial therapeutic agents. A pyrrole-fused piperazin-2-one scaffold 6 was prepared by reductive amination of pyrralines 5 with benzylamine. While further cyclization of pyrralines 5 with ethane-1,2-diamine produced pyrrolo-piperazin-2-ones 7 with an extra imidazolidine ring, the reaction with 2-amino alcohols derived from natural l-amino acids, alanine, valine, and phenylalanine, respectively provided pyrrolo-piperazin-2-ones 8, 9, and 10 with oxazolidine as the third structural core. Cell viability and an anti-inflammatory effect of the synthesized compounds were briefly tested by the MTT method and the Griess assay, among which 8h and 10g exhibited significant anti-inflammatory effects with negligible cell toxicity.

(2S, 3R)-3-amino-2-hydroxy-4-phenylbutyrylamide derivative as well as preparation method and application thereof

The invention discloses a (2S, 3R)-3-amino-2-hydroxy-4-phenylbutyrylamide derivative shown as a formula (I) or an optical isomer, a diastereomer and racemate mixture and pharmaceutically acceptable salt thereof as well as a preparation method and application of the (2S, 3R)-3-amino-2-hydroxy-4-phenylbutyrylamide derivative. It is shown by comparison of results of a positive control group and a model group on lymphedema prevention experiments that the compound disclosed in the invention shows obvious anti-edema activity.

Synthesis and anti-tumor activity of marine alkaloids

Marine alkaloids were divided into five categories from the perspective of anti-tumor activity. The optimization process, chemical synthesis, anti-tumor activity evaluation and structure–activity relationship of various compounds were discussed.

Preparation method of phosphodiesterase inhibitor

The invention discloses a preparation method of a phosphodiesterase inhibitor and belongs to the field of medicinal chemistry. The preparation method comprises the following steps: starting the raw material 1 and methanol to prepare the intermediate I without adding organic solvent crystallization. After the series of centrifugation, washing and drying, the intermediate II is directly condensed and cyclized with piperonal, and a final product tadalafil is prepared by chloroacetylation, aminolysis and refining steps. The method improves the product yield and quality, greatly shortens the reaction period, reduces the operation steps and the production cost, and is suitable for industrial mass production.

Pentacyclic indole quinolizine with inhibiting cell autophagy and synthesis method thereof as, well, as anti-tumor activity and application thereof

The invention discloses pentacyclic indole quinolizine inhibiting cell autophagy, i.e. (6S)-3-acetyl-6-(N-phenylacetylaminoacyl)-methyl oxide-4, 6, 7, 12-tetrahydro-4-oxoindole[2, 3-a]quinolizine, and also discloses synthesis, activity and application of the compound.

Design, synthesis and bio-evaluation of C-1 alkylated tetrahydro-β-carboline derivatives as novel antifungal lead compounds

The field of antifungal agent has become static and development of resistance by the pathogen as well as limited clinical efficacy of marketed drugs demand the constant development of new antifungals. The presence of hydrocarbon chain of specific length linked with various different heterocycles was found to be an important structural feature in various antifungal lead compounds. Based on the prominent antimicrobial activity of β-carboline derivatives, a set of C1 alkylated tetrahydro-β-carboline derivatives were proposed to be active against fungi. To validate and confirm the role of suitable alkyl chains linked to a β-carboline scaffold, few related analogues having C1 aryl substituents were also synthesized in one step via classic Pictet-Spengler reaction. The synthesized library was evaluated for its antifungal activity against C. albicans, C. krusei, C. parapsilosis, C. kefyr, C. glabrata, C. tropicalis and C. neoformans. One of the library members (compound 12c), with n-alkyl chain of eight carbons exhibited potent antifungal activity against C. glabrata and C. kefyr. The lead compound, being selectively toxic also demonstrated prominent synergy enhancing the potency of antifungal drugs up to 10-fold. The time kill kinetic studies confirmed the efficacy of compound 12c, where the results obtained were comparable to that of Amp B. FE-SEM analysis revealed the increased asymmetry, disintegration and roughness of cell surface which could be because of the possible interaction of compound 12c at membrane level or interference in cell wall structure. Apoptosis/necrosis detection assay confirmed the significant apoptotic activity in C. glabrata cells after 12c treatment which was responsible for the rapid killing of C. glabrata cells.